Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

Status Completed

Clinical Trial Summary

Objectives/Purpose:

To determine the safety and efficacy of a Vitamin K (Vit K) antagonist (warfarin) in treating Metachromatic Leukodystrophy (MLD).

Clinical Trial Description

Hypothesis:

Vit K has an essential role in biosynthesis of sulfatides and other sphingolopids in the brain. Administering warfarin, a Vit K antagonist, may ameliorate the phenotype in MLD by decreasing t he amount of sphingolipid storage in the neuronal cells.

Study Design Prospective: we will enroll eligible consenting subjects into the study. The study will not include a control group and the families and treating physicians are informed administration of the drug.

1. Duration of Treatment: 4 weeks

2. Pharmacological Intervention: The patients will receive warfarin 1.5 mg at the beginning of the study period. The dosage then will be adjusted to the INR values on weekly basis.

3. Clinical evaluation: The patients will undergo clinical assessment prior to starting the treatment and at the end of the treatment period. The clinical assessment will also include administration of Gross Motor Function Measure (GMFM), a clinical toll for evaluation of motor development in children.

4. Urine Sulfatide Quantification: Urine samples for quantification of the sulfatide level will be collected at the time of enrollment, after 2 weeks and at the end of treatment period.

5. Blood Monitoring: The patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5. If the INR is greater than 4.0 the dosage of warfarin will be lowered and another blood draw will be performed in 3 days. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00683189
Study type	Interventional
Source	The Cooper Health System
Contact
Status	Completed
Phase	N/A
Start date	June 2007
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00383448` - HSCT for High Risk Inherited Inborn Errors	Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT01303146` - Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Active, not recruiting	`NCT04628364` - The Natural History of Metachromatic Leukodystrophy Study (HOME Study)
Enrolling by invitation	`NCT05368038` - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Withdrawn	`NCT00639132` - The Natural History of Metachromatic Leukodystrophy
Active, not recruiting	`NCT01801709` - Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy	Phase 1/Phase 2
Recruiting	`NCT02171104` - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis	Phase 2
Active, not recruiting	`NCT02699190` - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Active, not recruiting	`NCT03392987` - A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)	Phase 2
Recruiting	`NCT02559830` - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy	Phase 1/Phase 2
Completed	`NCT00176904` - Stem Cell Transplant for Inborn Errors of Metabolism	Phase 2/Phase 3
Completed	`NCT00004378` - Stem Cell Transplantation (SCT) for Genetic Diseases	N/A
Active, not recruiting	`NCT04283227` - OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)	Phase 3
Recruiting	`NCT03047369` - The Myelin Disorders Biorepository Project
Recruiting	`NCT04925349` - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting	`NCT00005900` - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Active, not recruiting	`NCT01560182` - Gene Therapy for Metachromatic Leukodystrophy (MLD)	Phase 1/Phase 2
Completed	`NCT01586455` - Human Placental-Derived Stem Cell Transplantation	Phase 1